Non-Small Cell Lung Cancer (NSCLC) Market: Segmented: By histology (large cell carcinoma, adenocarcinoma and SCC or squamous cell carcinoma); By treatment (chemotherapy, radiation and surgery)and Region –Analysis of Market Size, Share & Trends for 2014 – 2019 and Forecasts to 2030.
Non-Small Cell Lung Cancer (NSCLC) Market By histology (large cell carcinoma, adenocarcinoma and SCC or squamous cell carcinoma); By treatment (chemotherapy, radiation and surgery)and Region -Analysis of Market Size, Share & Trends for 2014 - 2019 and Forecasts to 2030
PRODUCT OVERVIEW
Small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are two main types of lung cancer NSCLC is the most common type of lung cancer accounting for approximately 85% of all lung cancers (IASLC, n.d.).Any epithelial lung cancer other than SCLC can be classified as NSCLC.NSCLC may be in the middle of the chest, but often also in other parts of the lung. Although NSCLCs are associated with smoking, they can also be found in patients who never have smoked. Adenocarcinomas are also common. Furthermore, chemotherapy and radiation therapy are fairly insensitive compared to SCLC.NSCLC comes from the central bronchial epithelial lung cells to the terminal alveoli. The histological type NSCLC coincides with the site of origin and reflects the variation in bronchial to alveoli respiratory epithelium. Whereas adenocarcinoma and bronchioloalveolar cancer typically originate from the peripheral lung tissue near central bronchuscommon symptoms include thoracic pain, wheezing, squatting, heartburn, chronic bronchitis, and loss of appetite, fatigue, shortness of respiration, bone pain, trouble swallowing, and limb stubbornness.
MARKET HIGHLIGHTS
Non-Small Cell Lung Cancer (NSCLC) Market is expected to project a CAGR of 11.70% during the forecast period, 2021-2030
The Non-Small Cell Lung Cancer (NSCLC) market is anticipated to grow on the back of opportunities generated by the advent of the rising total number of lung cancer globally out of which Non-Small Cell Lung Cancer (NSCLC) holds a significant share. This has attracted the majority of the key leaders to focus on advancing therapeutics and increasing the efficiencies of the existing ones. This market is also driven by the existing status of lung cancer as the most widely occurring disease and the increase in the number of deaths it has caused. Also, an increase in the investments by the key leaders in research and developments and the introduction of Non-Small Cell Lung Cancer (NSCLC) therapeutics into the major market players is boosting the market globally.
GLOBAL NON-SMALL CELL LUNG CANCER (NSCLC) MARKET: SEGMENTS
The global Non-Small Cell Lung Cancer (NSCLC)market is based on histology
Market Dynamics
Drivers
Rapid industrialization
Restraints
GLOBAL NON-SMALL CELL LUNG CANCER (NSCLC) MARKET: KEY PLAYERS
Global Non-Small Cell Lung Cancer (NSCLC) Market Segments
PRODUCT OVERVIEW
Small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are two main types of lung cancer NSCLC is the most common type of lung cancer accounting for approximately 85% of all lung cancers (IASLC, n.d.).Any epithelial lung cancer other than SCLC can be classified as NSCLC.NSCLC may be in the middle of the chest, but often also in other parts of the lung. Although NSCLCs are associated with smoking, they can also be found in patients who never have smoked. Adenocarcinomas are also common. Furthermore, chemotherapy and radiation therapy are fairly insensitive compared to SCLC.NSCLC comes from the central bronchial epithelial lung cells to the terminal alveoli. The histological type NSCLC coincides with the site of origin and reflects the variation in bronchial to alveoli respiratory epithelium. Whereas adenocarcinoma and bronchioloalveolar cancer typically originate from the peripheral lung tissue near central bronchuscommon symptoms include thoracic pain, wheezing, squatting, heartburn, chronic bronchitis, and loss of appetite, fatigue, shortness of respiration, bone pain, trouble swallowing, and limb stubbornness.
MARKET HIGHLIGHTS
Non-Small Cell Lung Cancer (NSCLC) Market is expected to project a CAGR of 11.70% during the forecast period, 2021-2030
The Non-Small Cell Lung Cancer (NSCLC) market is anticipated to grow on the back of opportunities generated by the advent of the rising total number of lung cancer globally out of which Non-Small Cell Lung Cancer (NSCLC) holds a significant share. This has attracted the majority of the key leaders to focus on advancing therapeutics and increasing the efficiencies of the existing ones. This market is also driven by the existing status of lung cancer as the most widely occurring disease and the increase in the number of deaths it has caused. Also, an increase in the investments by the key leaders in research and developments and the introduction of Non-Small Cell Lung Cancer (NSCLC) therapeutics into the major market players is boosting the market globally.
GLOBAL NON-SMALL CELL LUNG CANCER (NSCLC) MARKET: SEGMENTS
The global Non-Small Cell Lung Cancer (NSCLC)market is based on histology
Market Dynamics
Drivers
Rapid industrialization
Restraints
GLOBAL NON-SMALL CELL LUNG CANCER (NSCLC) MARKET: KEY PLAYERS
- Rozlytrek (Entrectinib)
- Opdivo (Nivolumab)
- Tagrisso (Osimertinib)
- Vizimpro (Dacomitinib)
- Portrazza (Necitumumab)
- Imfinzi (Durvalumab)
- Vitrakvi (Larotrectinib)
Global Non-Small Cell Lung Cancer (NSCLC) Market Segments
- By histology
- large cell carcinoma
- adenocarcinoma
- SCC or squamous cell carcinoma
- By treatment
- chemotherapy,
- Radiation
- surgery
- Global Non-Small Cell Lung Cancer (NSCLC) Market Dynamics
- Global Non-Small Cell Lung Cancer (NSCLC) Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies Involved in the Market
- Value Chain of the Market
- Market Drivers and Restraints
- Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 3-month post-sales analyst support.
1. EXECUTIVE SUMMARY
2. NON-SMALL CELL LUNG CANCER (NSCLC)
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. RESEARCH METHODOLOGY
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. AVERAGE PRICING ANALYSIS
5. MARKET DYNAMICS
5.1. Growth Drivers
5.2. Restraints
5.3. Opportunity
5.4. Trends
6. CORRELATION & REGRESSION ANALYSIS
6.1. Correlation Matrix
6.2. Regression Matrix
7. RECENT DEVELOPMENT, POLICIES®ULATORY LANDSCAPE
8. RISK ANALYSIS
8.1. Demand Risk Analysis
8.2. Supply Risk Analysis
9. NON-SMALL CELL LUNG CANCER (NSCLC) INDUSTRY ANALYSIS
9.1. Porters Five Forces
9.1.1. Threat of New Entrants
9.1.2. Bargaining Power of Suppliers
9.1.3. Threat of Substitutes
9.1.4. Rivalry
9.2. PEST Analysis
9.2.1. Political
9.2.2. Economic
9.2.3. Social
9.2.4. Technological
10. GLOBAL NON-SMALL CELL LUNG CANCER (NSCLC) MARKET
10.1. Market Size & forecast, 2019A-2030F
10.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11. GLOBAL NON-SMALL CELL LUNG CANCER (NSCLC) MARKET: MARKET SEGMENTATION
11.1. By Regions
11.1.1. North America:(U.S. and Canada)
11.1.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America)
11.1.2.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe)
11.1.3.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific)
11.1.4.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.1.5. The Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of the Middle East and Africa)
11.1.5.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.2. By Histology Market Share (2020-2030F)
11.2.1. Large cells carcinoma, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.2.2. Adenocarcinoma, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.2.3. SCC or Squamous cell, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.3. By Treatment: Market Share (2020-2030F)
11.3.1. Chemotherapy, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.3.2. Radiation, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.3.3. Surgery, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12. COMPANY PROFILE
12.1. Rozlytrek (Entrectinib): Hofmann –La Roche
12.1.1. Company Overview
12.1.2. Company Total Revenue (Financials)
12.1.3. Market Potential
12.1.4. Global Presence
12.1.5. Key Performance Indicators
12.1.6. SWOT Analysis
12.1.7. Product Launch
12.2. Opdivo (Nivolumab): Bristol-Myers Squibb
12.3. Tagrisso (Osimertinib): AstraZeneca
12.4. Vizimpro (Dacomitinib): Pfizer
12.5. Portrazza (Nacitumumab): Eli Lilly and Company
12.6. Imfinzi (Durvalumab): AstraZeneca.
12.7. Vitrakvi (Larotrectinib): Bayer Healthcare
12.8. Other Prominent Players
Consultant Recommendation
The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
